8-K: Catheter Precision Enacts 1-for-19 Reverse Stock Split

Catheter Precision, Inc. has completed a 1-for-19 reverse stock split, reducing outstanding shares and adjusting equity instruments.

Summary

• Catheter Precision, Inc. (VTAK) completed a 1-for-19 reverse stock split of its common stock.
• The reverse stock split became effective on August 15, 2025, at 12:01 a.m. Eastern Time.
• Common Stock began trading on a split-adjusted basis on the NYSE American on August 15, 2025.
• The number of issued and outstanding shares of Common Stock was reduced from approximately 23,327,516 to approximately 1,227,764.
• The company's trading symbol (VTAK) remains unchanged, but a new CUSIP number (74933X 708) has been assigned.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive pro rata net proceeds from their sale.
• Proportionate adjustments were made to outstanding stock options, warrants, stock incentive plans, and preferred stock conversion prices/ratios.
• The authorized capital stock of 10 million shares of Preferred Stock and 60 million shares of Common Stock remains unchanged.

Sentiment

Score: 3

Explanation: The reverse stock split is a defensive corporate action often taken to avoid delisting due to a low share price. While it achieves the technical goal of increasing the per-share price, it typically reflects underlying challenges and is often viewed negatively by the market, indicating a lack of organic growth or investor confidence. The significant 1-for-19 ratio further underscores the severity of the situation.

Positives

• The reverse stock split may help the company meet minimum bid price requirements of the NYSE American, potentially preventing delisting.
• A higher per-share price might make the stock more attractive to institutional investors and funds that have minimum price requirements.
• The proportionate adjustments to equity instruments ensure no change in stockholders' percentage ownership or voting power, except for immaterial fractional share effects.

Negatives

• Reverse stock splits are often perceived negatively by the market, signaling underlying financial distress or a lack of organic share price appreciation.
• The reduction in outstanding shares could lead to lower trading liquidity.
• There is a risk that the stock price may continue to decline post-split, negating the intended effect of increasing the per-share price.
• The treatment of fractional shares means some stockholders will be cashed out for small amounts, potentially incurring brokerage fees.

Risks

• Risk of continued stock price decline post-split, potentially leading to further compliance issues or negative market perception.
• Reduced liquidity due to fewer outstanding shares.
• Negative investor sentiment associated with reverse stock splits, which can deter new investment.
• Potential for the company to fail to achieve sustained compliance with exchange listing standards despite the split.

Future Outlook

Proportionate adjustments have been made to outstanding stock options, warrants, and stock incentive plans, as well as preferred stock conversion prices, to reflect the reverse stock split. This suggests an ongoing commitment to existing equity compensation and financing structures, adjusted for the new share count.

Management Comments

• The Board determined to effect a reverse split of the Common Stock at a ratio of 1-for-19.
• The Reverse Stock Split affects all stockholders uniformly and will not change any stockholders percentage ownership interest or any stockholders proportionate voting power, except for immaterial changes that may result from the treatment of fractional shares.

Industry Context

Reverse stock splits are typically undertaken by companies whose stock price has fallen significantly, often below exchange minimum bid requirements. In the medical device industry, maintaining exchange listing is crucial for visibility and access to capital. This action suggests Catheter Precision is addressing a low share price, a common challenge for smaller or developing companies in the highly competitive and capital-intensive healthcare technology sector, where sustained profitability can take time.

Comparison to Industry Standards

• Many companies, particularly those in the biotech and medical device sectors, resort to reverse stock splits to maintain listing compliance on major exchanges like the NYSE American.
• For example, companies like Aeterna Zentaris Inc. (AEZS) or Sorrento Therapeutics, Inc. (SRNEQ) have executed similar reverse splits to boost their per-share price and avoid delisting.
• While the specific financial performance leading to this action is not detailed, the 1-for-19 ratio is a significant consolidation, indicating a substantial need to increase the per-share price. This is a common strategy but does not inherently guarantee long-term stock price appreciation or improved business fundamentals.

Corporate Governance

Stakeholder Impact

• Shareholders: Immediate reduction in the number of shares held, with a proportionate increase in per-share price. Those with fractional shares will be cashed out. No change in percentage ownership or voting power (except for fractional share effects).
• Employees (with equity awards): Stock options and warrants, and shares available under stock incentive plans, will be proportionately adjusted, maintaining the intrinsic value of their equity awards.
• Creditors: No direct impact mentioned, but a reverse split can signal financial weakness, which might indirectly affect credit perception.

Next Steps

• Continued trading of Common Stock under VTAK symbol on NYSE American on a split-adjusted basis.
• Exchange agent to aggregate and sell fractional shares, distributing net proceeds to entitled stockholders.
• Ongoing adjustments to equity instruments (options, warrants, incentive plans, preferred stock) to reflect the new share count.

Key Dates

Recommendation

The reverse stock split is a necessary corporate action to maintain listing compliance on the NYSE American, which is a positive for the company's market presence. However, it is often a sign of underlying challenges and does not inherently improve business fundamentals or guarantee future stock price appreciation. Investors should hold to observe if the company can leverage this action to improve its operational performance and regain investor confidence, as the risk of further price decline remains.

Keywords

Catheter Precision, VTAK, Reverse Stock Split, Stock Split, NYSE American, Corporate Action, Share Consolidation, SEC Filing, 8-K, Medical Devices